Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
NCT05892393
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This study is testing a new type of imaging called [89Zr]DFO-YS5 positron emission tomography (PET) to see if it is safe and effective at finding cancer cells in patients with multiple myeloma. [89Zr]DFO-YS5 is a special kind of material that is put into the body to help doctors see different parts of the body. It focuses on a specific protein called CD46 that is found in some multiple myeloma cells. The hope is that the [89Zr]DFO-YS5 PET scans can help doctors detect multiple myeloma better.
This study is testing a new type of imaging called [89Zr]DFO-YS5 positron emission tomography (PET) to see if it is safe and effective at finding cancer cells in patients with multiple myeloma. [89Zr]DFO-YS5 is a special kind of material that is put into the body to help doctors see different parts of the body. It focuses on a specific protein called CD46 that is found in some multiple myeloma cells. The hope is that the [89Zr]DFO-YS5 PET scans can help doctors detect multiple myeloma better.
Third Opinion AI Generated Synopsis
Trial Summary
This phase I trial tests the safety of \[89Zr\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \[89Zr\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \[89Zr\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \[89Zr\]DFO-YS5 PET scans may improve detection of multiple myeloma.
This phase I trial tests the safety of \[89Zr\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \[89Zr\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \[89Zr\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \[89Zr\]DFO-YS5 PET scans may improve detection of multiple myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
